FDA Drops Official Playbook for Psychedelic Clinical Trials
Published Date: 7/14/2026
Notice
Summary
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Guidance for Psychedelic Trial Design
The FDA issued a final guidance on July 14, 2026 called "Psychedelic Drugs: Considerations for Clinical Investigations" that gives sponsors recommendations for designing clinical trials of investigational psychedelic products for medical conditions (for example, psychiatric disorders and substance use disorders). The guidance discusses study design, data collection and generation, and patient monitoring, and it finalizes the draft issued on June 26, 2023.
Questionnaire Recommendations for Trials
The guidance recommends using questionnaires to assess clinical trial subjects' expectations about potential drug effects and to collect end-of-treatment information to improve how trial data are interpreted. This is a recommended data-collection practice described in the July 14, 2026 final guidance.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
Previous / Next Documents
Previous: 2026-14157 — Hazardous Materials: Notice of Applications for Modification to Special Permits
The Department of Transportation is letting folks know they’ve received requests to change special permits for safely moving hazardous materials. These changes could affect companies using trucks, trains, ships, or planes to transport dangerous goods. If you want to share your thoughts, you’ve got until July 29, 2026, to send in comments—no fees involved, just your voice!
Next: 2026-14159 — Agency Information Collection Activities; Comment Request; eZ-Audit: Electronic Submission of Financial Statements and Compliance Audits
The Department of Education is keeping its eZ-Audit system for submitting financial statements and compliance audits online, with no changes. This affects schools and organizations that report financial info to the government, giving them more time to comment until September 14, 2026. No new costs or rules are coming—just a smooth extension to keep things easy and electronic!